PeptideDB

Mimosine

CAS No.: 500-44-7

L-Mimosine (Leucenol) is an antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca and acts
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description L-Mimosine (Leucenol) is an antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca and acts as an iron chelator.
In vitro L-Mimosine 在PC-3细胞中阻断细胞周期的G1期,在LNCaP细胞中阻断S期,因此抑制了细胞增殖。[1] 作为脯氨酸羟化酶(PHD)抑制剂的L-Mimosine,可以刺激VEGF的产生,并在源自牙髓的细胞中增加它们的促血管生成能力。[2]
In vivo L-mimosine (50 mg/kg i.p.) 在 Sprague-Dawley 大鼠中明显上调肾脏中的 HIF-1alpha 表达,并显著增强对肾灌注压的利尿反应。[3]
Cell experiments Cell proliferation in response to L-mimosine is measured using a [3H]thymidine incorporation assay. In this assay, 1 × 104 cells are cultured in each well of a 12-well plate in RPMI-1640 medium with 10% FCS and different concentrations (0–800 μM) of L-mimosine. After the required incubation periods (24 and 48 h), 0.5 μCi/ml of [3H]thymidine is added to each well of the 12-well plate. The cells are then incubated at 37°C in a humidified 5% CO2 atmosphere for 4 h. Cells are then washed twice with cold phosphate-buffered saline (PBS) and then with cold 5% trichloroacetic acid. Cells are lysed by adding 0.5 ml of 0.5 N NaOH. Then 400 μl of the solubilized cell solution are mixed with 4 ml of scintillation cocktail and counted in a liquid scintillation analyzer . Each sample was tested in quadruplicate.(Only for Reference)
Synonyms Leucenine, NSC 69188, 含羞草素, Leucenol, L-Mimosine
molecular weight 198.18
Molecular formula C8H10N2O4
CAS 500-44-7
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 0.01 mg/mL (0.05 mM) H2O: < 1 mg/mL (insoluble or slightly soluble)
References 1. Chung LC, et al. Am J Physiol Cell Physiol. 2012, 302(4), C676-685. 2. Müller HD, et al. J Endod. 2012, 38(11), 1498-1503.. 3. Li N, et al. Am J Physiol Renal Physiol. 2007, 292(1), F207-216.